← Back to Clinical Trials
Recruiting NCT07493213

NCT07493213 USG-Guided Shoulder Injections in Frozen Shoulder

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07493213
Status Recruiting
Phase
Sponsor Konya Beyhekim Training and Research Hospital
Condition Frozen Shoulder
Study Type INTERVENTIONAL
Enrollment 68 participants
Start Date 2026-04-01
Primary Completion 2027-05-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
USG-guided suprascapular nerve blockUSG-Guided suprascapular nerve block plus subacromial injection.

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 68 participants in total. It began in 2026-04-01 with a primary completion date of 2027-05-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Frozen shoulder (adhesive capsulitis) is characterized by pain and a progressive restriction of both active and passive shoulder range of motion, significantly impairing daily activities and quality of life. This study aims to evaluate the effectiveness of USG-guided shoulder injections, when added to a home-based exercise program, in the conservative management of patients with chronic, painful frozen shoulder. In this prospective randomized study, patients diagnosed with painful frozen shoulder will be included. In addition to a standardized home-based exercise program, patients will receive either USG-guided suprascapular nerve block alone or a combination of suprascapular nerve block and subacromial injection. The effects of these approaches on clinical outcomes will be assessed over a 20-week follow-up period. Primary outcome measures include pain intensity assessed by the Visual Analog Scale (VAS), functional status evaluated by the Shoulder Pain and Disability Index (SPADI), and shoulder range of motion. Secondary outcomes include depression level (Beck Depression Inventory), sleep quality, pain phenotype (nociplastic, neuropathic, or nociceptive), hand grip strength, ultrasonographic findings ( (coracohumeral ligament thickness, subacromial bursa thickness) , and patient satisfaction (subjective impression of improvement). The results of this study are expected to provide evidence on the comparative effectiveness and additional benefits of different shoulder injection approaches when combined with home-based exercise therapy in patients with chronic frozen shoulder.

Eligibility Criteria

Inclusion Criteria: Age between 18 and 75 years and willingness to participate in the study Presence of shoulder pain lasting at least 3 months and a diagnosis of primary frozen shoulder Pain intensity ≥ 4/10 on the Visual Analog Scale (VAS), resistant to medical treatment/analgesics Restriction of ≥30 degrees in at least two planes of shoulder motion (flexion, abduction, or external rotation) \- Exclusion Criteria: * History of shoulder trauma Presence of neurological conditions such as stroke, brachial plexus injury, Parkinson's disease, or cervical spine pathology with or without radiculopathy History of shoulder surgery, shoulder malignancy or tumor, or prior shoulder manipulation Presence of shoulder arthritis, rotator cuff tear, other shoulder injuries, or thoracic outlet syndrome Systemic diseases affecting the shoulder, severe degeneration or trauma (e.g., osteoarthritis, rheumatoid arthritis, labral or articular cartilage injuries), or inflammatory rheumatic diseases Steroid injection to the affected extremity within the last 3 months, use of oral steroids or NSAIDs, or ongoing surgical/interventional treatment Pregnancy or lactation Uncontrolled diabetes, heart failure, or uncontrolled systemic diseases (e.g., liver failure, chronic kidney disease, significant endocrine disorders) Communication problems or severe psychiatric disorders

Contact & Investigator

Central Contact

Fulya Ece URKAN, MD

✉ ece.1608@hotmail.com

📞 +905068994339

Principal Investigator

Ramazan YILMAZ, Associate Professor (MD)

STUDY DIRECTOR

Konya Beyhekim Training and Research Hospital

Frequently Asked Questions

Who can join the NCT07493213 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Frozen Shoulder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07493213 currently recruiting?

Yes, NCT07493213 is actively recruiting participants. Contact the research team at ece.1608@hotmail.com for enrollment information.

Where is the NCT07493213 trial being conducted?

This trial is being conducted at Konya, Turkey (Türkiye).

Who is sponsoring the NCT07493213 clinical trial?

NCT07493213 is sponsored by Konya Beyhekim Training and Research Hospital. The principal investigator is Ramazan YILMAZ, Associate Professor (MD) at Konya Beyhekim Training and Research Hospital. The trial plans to enroll 68 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology